Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review

December 2021 | 61 pages | ID: BFFC7371C30EN
GlobalData

Abstracts

Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Boehringer Ingelheim International GmbH Key Recent Developments

Oct 27,2021: Boehringer Ingelheim opens high-tech tablet production facility in Ingelheim
Oct 25,2021: Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
Oct 19,2021: Boehringer Ingelheim and partners to accelerate development of first-in-class gene therapy for patients with cystic fibrosis
Oct 12,2021: Boehringer Ingelheim launches University of Medicine Excellence
Oct 07,2021: Boehringer Ingelheim opens $809.2m biopharmaceutical plant in Austria

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Boehringer Ingelheim International GmbH - Key Facts
Boehringer Ingelheim International GmbH - Key Employees
Boehringer Ingelheim International GmbH - Key Employee Biographies
Boehringer Ingelheim International GmbH - Major Products and Services
Boehringer Ingelheim International GmbH - History
Boehringer Ingelheim International GmbH - Company Statement
Boehringer Ingelheim International GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Boehringer Ingelheim International GmbH - Business Description
Business Segment: Animal Health
Overview
Performance
Key Stats
Business Segment: Biopharmaceutical Contract Manufacturing
Overview
Performance
Business Segment: Human Pharmaceuticals
Overview
Performance
Key Stats
Business Segment: Other Sales
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia/Australia/Africa
Performance
Geographical Segment: Europe
Performance
R&D Overview
Boehringer Ingelheim International GmbH - Corporate Strategy
Boehringer Ingelheim International GmbH - SWOT Analysis
SWOT Analysis - Overview
Boehringer Ingelheim International GmbH - Strengths
Boehringer Ingelheim International GmbH - Weaknesses
Boehringer Ingelheim International GmbH - Opportunities
Boehringer Ingelheim International GmbH - Threats
Boehringer Ingelheim International GmbH - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Boehringer Ingelheim International GmbH, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Oct 27, 2021: Boehringer Ingelheim opens high-tech tablet production facility in Ingelheim
Oct 25, 2021: Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
Oct 19, 2021: Boehringer Ingelheim and partners to accelerate development of first-in-class gene therapy for patients with cystic fibrosis
Oct 12, 2021: Boehringer Ingelheim launches University of Medicine Excellence
Oct 07, 2021: Boehringer Ingelheim opens $809.2m biopharmaceutical plant in Austria
Sep 17, 2021: Boehringer Ingelheim and Amgen collaborate on cancer trial
Sep 08, 2021: CDR-Life announces the advancement of antibody treatment for patients with geographic atrophy with development partner Boehringer Ingelheim
Aug 04, 2021: Columbia Clinic signed a cooperation agreement with Boehringer Ingelheim
Aug 03, 2021: Nanoform and Boehringer Ingelheim execute master services agreement
Aug 03, 2021: First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Boehringer Ingelheim International GmbH, Key Facts
Boehringer Ingelheim International GmbH, Key Employees
Boehringer Ingelheim International GmbH, Key Employee Biographies
Boehringer Ingelheim International GmbH, Major Products and Services
Boehringer Ingelheim International GmbH, History
Boehringer Ingelheim International GmbH, Other Locations
Boehringer Ingelheim International GmbH, Subsidiaries
Boehringer Ingelheim International GmbH, Key Competitors
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Boehringer Ingelheim International GmbH, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021